Direct-to-Patient (DtP): The Future of Clinical Trials

Key Takeaways

The Retention Revolution: Travel is the primary reason for a 30% patient dropout rate. Moving the clinical site to the home removes this barrier.

ICH E6(R3) Readiness: Singapore's Health Sciences Authority (HSA) has implemented the updated ICH E6(R3) standards as of 1 January 2026, requiring a Quality by Design approach.

Unbroken Chain of Custody: Keeping unapproved medicines stable outside a clinic needs IoT sensors and white-glove delivery to ensure product integrity.

Scalable Compliance: Success in ASEAN requires navigating a complex patchwork of medical licenses and varied remote delivery environments.

Traditional site-centric models of research are hitting a wall in 2026. Recruitment goals are often missed because patients cannot manage the time and travel for hospital visits. We've built the DHL Health Logistics network to solve this challenge directly. Our 2-billion-euro investment ensures you have the GDP-certified infrastructure and specialised handling needed to reach patients anywhere. Direct-to-Patient (DtP) clinical trials move the laboratory to the living room while keeping the highest levels of safety and regulatory compliance.

Why is patient retention the biggest risk in 2026 clinical research?

Travel is the main reason participants leave clinical studies. When you move the trial site to the patient, you reduce missed visits and screen failures.

Travel Distance: Cancer trial patients travel a median of nearly 42 miles for Phase I studies.

Rural Hurdles: Participants in remote areas across Southeast Asia often face significant logistical challenges.

Human Connection: Technical couriers act as a professional extension of the clinical site at the doorstep.

Supportive Experience: White-glove services go beyond simple delivery to build participant trust and confidence in the trial.

DHL Health Logistics provides the professional bridge between your lab and the participant. We understand that a courier is often the only face of the trial that a patient sees, making reliability and professionalism paramount.

What are the 2026 regulatory requirements for DtP?

Regulators, led by Singapore’s Health Sciences Authority (HSA), are rapidly updating rules to support decentralised models. The new ICH E6(R3) guidelines, implemented by the HSA from 1 January 2026, require you to prove the drug remained stable from the depot to the patient’s refrigerator.

Mandatory Adoption: Singapore's HSA has adopted the Principles and Annex 1 of the ICH E6(R3) Guideline for Good Clinical Practice (GCP) as of 1 January 2026.

Strict Accountability: The HSA's focus on a risk-proportionate approach demands robust and verifiable temperature records throughout the supply chain.

Thermal Protection: Advanced shippers maintain 2 to 8°C or -20°C for up to 120 hours, critical for shipments from Changi Airport to destinations across the region.

Digital Proof: IoT sensors transmit live data to show exactly when a participant received the shipment, providing a complete audit trail.

Our investment in digital tools ensures you have a full thermal audit trail. This transparency is a requirement for satisfying quality assurance teams and the Health Sciences Authority (HSA).

How do you handle medical license restrictions in emerging markets?

Delivering unapproved medicines to a private address is strictly regulated across ASEAN. As a regional hub, Singapore-based logistics managers need a partner who understands the specific Ministry of Health decrees in markets like Indonesia or Vietnam.

Regional Complexity: Regulatory systems across Asia are not harmonised, creating significant compliance challenges for multi-country trials.

Customs Expertise: Navigating the import requirements for clinical trial materials in each ASEAN country is critical to avoid costly delays.

Expert Navigation: Our local specialists work with bodies like the HSA to keep your trial on track, leveraging Singapore's robust Free Trade Agreements to streamline regional distribution.

Expanded Footprint: Proper licensing allows you to reach regions that were previously considered too complex, managed from a central hub in Singapore.

Can a secure chain of custody at the doorstep be guaranteed?

Security and privacy are vital when delivering sensitive products to a home. You must ensure the medicine is handed directly to the verified participant or their legal representative, in full compliance with HSA guidance.

Identity Verification: We check IDs against trial records before any package is handed over.

Instruction Support: We confirm the patient knows how to handle the packaging and materials as per the trial protocol.

Safe Disposal: We collect used kits or sharp containers for medical-grade destruction, closing the logistics loop securely.

What is the role of reverse logistics in home-based trials?

A DtP trial does not end at the doorstep. You must also manage the flow of biological samples and unused drugs from diverse locations back to a central lab in Singapore.

Stability Windows: Blood or urine samples must be collected and returned within strict time limits to be viable.

Data Integrity: If a sample deviates from its required temperature during transit, the trial data is compromised.

Remote Reach: We use specialised transport to reach participants in less accessible areas across the region, ensuring connectivity back to Singapore.

Unified Visibility: A clinical research associate in Singapore should see the same real-time data as a sponsor in Europe, managed through a single platform like MyDHL+.

Ready to streamline your clinical trial strategy?

Direct-to-Patient logistics is no longer just a future concept. It’s the best way to improve the patient experience and protect your data. DHL Health Logistics is ready to help you scale your research from Singapore across the ASEAN region. Speak to a DHL specialist today to check your trial plan and reach your participants with confidence.

Frequently Asked Questions